Expert Interview
Discussing the potential of sibeprenlimab from Otsuka Pharmaceutical and the data from the Phase 3 Visionary Study for IgA Nephropathy (IgAN)
Ticker(s): OTSKYInstitution: Baylor/Texas A&M
- Clinical Assistant Professor of Medicine at Texas A&M University, Staff Physician at the Baylor Regional Transplant Institute, and partner at Dallas Nephrology Associates
- Manages 75 patients a week with kidney disease with a focus on chronic kidney disease, end stage renal disease, transplantation, and dialysis.
- Active in clinical research and is published in international journals in both nephrology and transplantation.
What are your thoughts on the safety profile of sibeprenlimab for treating IgA nephropathy?
Added By: ben_adminHow many patients with IgAN do you manage?
Added By: ben_adminWhere would sibeprenlimab fit into your treatment approach for IgAN?
Added By: ben_adminHow does sibeprenlimab compare to other APRIL inhibitory agents?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
